Pertussis, diphtheria, and tetanus (DTP)-containing vaccines combined with polio vaccines are recommended by the World Health Organization as part of routine immunization programs. The decline of immunity after vaccination has been considered as a possible reason for the reemergence of vaccine-preventable diseases worldwide. In this study, we evaluated the potential duration of protective immunity of pertussis, diphtheria, tetanus, and polio through a systematic review and meta-analysis. We examined data on immunological and clinical outcomes. We observed evidence of waning postvaccination immunity for pertussis and diphtheria, whereas tetanus and polio vaccines provided sustained protection. Further research on the risk factors of waning immunity after vaccination and the optimal timing of booster doses for pertussis and diphtheria is needed.

during childhood. Further doses of the diphtheria–tetanus vaccine are recommended every ten years. Protection can be verified by measuring the antitoxin Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Most infections are asymptomatic or have a mild clinical course, but in some outbreaks, the mortality rate approaches 10%. Signs and symptoms may vary from mild to severe, and usually start two to five days after exposure. Symptoms often develop gradually, beginning with a sore throat and fever. In severe cases, a grey Diphtheria prevention relies primarily on vaccination with the diphtheria toxoid, an inactivated form of the toxin produced by Corynebacterium diphtheriae. Introduced in the 1920s and widely adopted after World War II, the toxoid vaccine triggers strong antitoxin immunity that prevents the severe respiratory and systemic effects of the disease. Today, it is administered as part of combination vaccines such as DTaP (for children) and Tdap or Td (for adolescents and adults), with booster doses recommended every 10 years to maintain protection. Widespread immunization has reduced diphtheria from a common childhood killer to a rare disease in most countries, though cases can still occur in areas with low vaccination coverage. Pentavalent vaccines, which vaccinate against diphtheria and four other childhood diseases simultaneously (diphtheria, tetanus, pertussis [whooping cough], hepatitis B, and haemophilus influenzae type b [Hib]), are frequently used in disease prevention programs in developing countries by organizations such as UNICEF.

Immunization aginast tetanus with aluminium free-versus aluminium contain triple vaccine. In order to discover if elimination of aluminium from the very effective triple vaccine gives an unsatisfactory immunity against tetanus, the following investigation has been performed. 47 children were immunized in 1968 and 1969 during the first year of life with 3 injections of aluminium free triple vaccine given with an interval of 4--6 weeks. The vaccine contained 10 Lf tetanus toxoid per dose. 8 years later, during 1976 and 1977, they were given boosters containing aluminium adsorbed Td with 4 Lf tetanus toxoid. The above mentioned group was compared with 29 children immunized in the 1950's in the same way but with aluminium adsorbed triple vaccine (13--19 Lf tetanus toxoid per dose). The booster with DT given 6 to 7 years later contained 8 Lf aluminium adsorbed tetanus toxoid. The serum content of tetanus antitoxin was determined before and after the booster. The result showed that the tetanus immunity was very satisfactory even though the basic immunization was performed with aluminium free triple vaccine. Published in Developments in biological standardization (1979)

doses, almost everyone is initially immune, but additional doses every ten years are recommended to maintain immunity. A booster shot should be given within Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every ten years are recommended to maintain immunity. A booster shot should be given within 48 hours of an injury to people whose immunizatio Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every ten years are recommended to maintain immunity. A booster shot should be given within 48 hours of an injury to people whose immunization is out of date. Confirming that pregnant women are up to date on tetanus immunization during each pregnancy can prevent both maternal and neonatal tetanus. The vaccine is very safe, including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscle pain occurs in less than 10% of people. Severe allergic reactions occur in fewer than one in 100,000 people. A number of vaccine combinations include the tetanus vaccine, such as DTaP and Tdap, which contain diphtheria, tetanus, and pertussis vaccines, and DT and Td, which contain diphtheria and tetanus vaccines. DTaP and DT are given to children less than seven years old, while Tdap…

<h4>Background</h4>Acute lymphoblastic leukemia is the most prevalent childhood cancer and the leading cause of cancer mortality before the age of 20. Although therapeutic advances have significantly improved survival, children and adolescents treated for acute lymphoblastic leukemia remain vulnerable to infections, largely preventable by vaccination, due to humoral and cellular immune dysfunction induced by disease and treatment.<h4>Materials and methods</h4>This systematic review, based on electronic databases, aims to evaluate antibody levels associated with potential protective immunity against vaccine antigens for diphtheria, pertussis, tetanus, poliomyelitis, <i>Haemophilus influenzae</i> type b, measles, mumps, rubella, influenza, varicella-zoster virus, yellow fever, pneumococcal, and meningococcal diseases in children and adolescents treated for acute lymphoblastic leukemia after completion of chemotherapy.<h4>Results</h4>A total of twenty-four studies published between 1981 and 2023 were included, comprising 1110 children and adolescents. Protective antibody levels ranged from 11% to 97% for diphtheria, 0% to 90% for pertussis, 20% to 100% for tetanus, and 11% to 95% for poliomyelitis. <i>Haemophilus influenzae</i> type b, protection ranged from 16.7% to 100%. Viral vaccines also showed heterogeneous responses, with protection rates of 25-79% for mumps, 16-86% for measles, 35-98% for rubella, and 23-75% for varicella-zoster virus. Antibody responses to pneumococcal and meningococcal vaccines were consistently low, with protection rates of 5-38% for pneumococcal studies and 12% in a single meningococcal study.<h4>Conclusions</h4>This review found a consistent and clinically relevant loss of vaccine-induced immunity in children and adolescents treated for acute lymphoblastic leukemia. The recommendation of vaccine booster doses for this vulnerable population, irrespective of serological status, may represent a more practical approach to ensuring adequate post-chemotherapy treatment protection.

The causative agent of tetanus, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focussed on prevention using vaccination and post-exposure wound care. Medline, Pubmed and Cochrane databases; World Health Organization and United Nations Children's Fund publications. The maternal and neonatal tetanus elimination initiative has resulted in significant reductions in mortality from neonatal tetanus throughout the world. Although there are few data available it is likely that large numbers of children and adults, particularly men, remain unprotected due to lack of booster immunization. It remains unclear how HIV and malaria affect both responses to vaccination and transplacental transfer of antibodies or how this might affect timing of vaccination doses.

Unexpectedly, 3 mechanics seemed to develop immunity after coming into contact with machine fluids. From the results reported here, it is concluded that tetanus immunity in vaccinated individuals should be renewed by a compulsory booster injection given every 5, 10 or, at the minimum, 15 years. Moreover, high-risk populations such as that represented by the mechanics should be immunized or boostered on commencing employment. Published in Annales de microbiologie (1978)

‘‘when was your last tetanus booster?’’ Adequate immuniza- tion with tetanus ‘‘toxoid,’’ the inactivated … sequence as a child, a booster dose of the tetanus-diphtheria (T-d) vaccine every ten years gives protection … is less effective. Booster shots are needed every three years to maintain immunity. A low dose of vaccine

smallpox vaccine every five years and tetanus toxoid booster every ten years as 101D)s 584 Lewis L. CoRIELL … infants and the recommended booster doses are designed to insure or maintain immunity. Protection of infants … primary smallpox vaccination is recommended at 15 to 18 months of age together with the booster of DTP and